MoonLake Immunotherapeutics: Pay

MoonLake Immunotherapeutics paid its 3 named executives $14.4M in total in FY2025 (Dec). CEO Dr. Jorge Santos da Silva was paid $4.9M of that.

Pay$100 in the stock at the end of FY21 → $133
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Dr. Jorge Santos da SilvaChief Executive Officer and Interim Chair of the Board
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Dr. Kristian ReichChief Scientific Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Matthias BodenstedtChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 5 peers with pay on file was $7.0M. The CEO of MoonLake Immunotherapeutics was paid $4.9M, 29% below the median.

  1. 1Protagonist Therapeutics
  2. 2Immunovant
  3. 3Vera Therapeutics
  4. 4Spyre Therapeutics
  5. 5Celldex Therapeutics
  6. 6MoonLake Immunotherapeutics
  7. 7Akero TherapeuticsNot disclosed
  8. 8Apellis PharmaceuticalsNot disclosed
  9. 9Apogee TherapeuticsNot disclosed
  10. 10Arcus BiosciencesNot disclosed
  11. 11Bicycle TherapeuticsNot disclosed
  12. 12Crinetics PharmaceuticalsNot disclosed
  13. 13Kiniksa PharmaceuticalsNot disclosed
  14. 14PharvarisNot disclosed
  15. 15Summit TherapeuticsNot disclosed
  16. 16Verona PharmaNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.